BlackRock Fund Advisors’s Fate Therapeutics FATE Stock Holding History

BlackRock Fund Advisors’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$169K	Buy	67,239 +1,700	+3%	+$4.55K	﹤0.01%	3466
2016 Q3	$204K	Sell	65,539 -10,033	-13%	-$24.3K	﹤0.01%	3444
2016 Q2	$128K	Buy	75,572 +15,701	+26%	+$28.5K	﹤0.01%	3595
2016 Q1	$108K	Sell	59,871 -4,740	-7%	-$9.76K	﹤0.01%	3647
2015 Q4	$218K	Buy	64,611 +2,073	+3%	+$8.71K	﹤0.01%	3496
2015 Q3	$333K	Sell	62,538 -1,656	-3%	-$11.3K	﹤0.01%	3303
2015 Q2	$415K	Buy	64,194 +41,788	+187%	+$250K	﹤0.01%	3260
2015 Q1	$110K	Sell	22,406 -1,520	-6%	-$7.53K	﹤0.01%	3602
2014 Q4	$120K	Buy	23,926 +1,710	+8%	+$7.55K	﹤0.01%	3591
2014 Q3	$113K	Sell	22,216 -1,615	-7%	-$9.35K	﹤0.01%	3617
2014 Q2	$150K	Buy	23,831 +680	+3%	+$4.79K	﹤0.01%	3565
2014 Q1	$225K	Buy	+23,151	New	+$179K	﹤0.01%	3434

Other funds holding FATE

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock Fund Advisors's FATE Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Fate Therapeutics (FATE) stake by 2.6% in Q4 2016, buying an estimated $4.55K and bringing the position to 67,239 shares worth $169K. The position accounts for ﹤0.01% of the portfolio, ranked #3466.

BlackRock Fund Advisors first reported a position in FATE in Q1 2014 and has held it in 12 quarters since. The position peaked at $415K in Q2 2015. 37 funds tracked by Wall St. Rank hold FATE as of Q4 2016.

BlackRock Fund Advisors held 67,239 shares of Fate Therapeutics worth $169K as of Q4 2016.
BlackRock Fund Advisors bought 1,700 Fate Therapeutics shares in Q4 2016, an estimated $4.55K.
Fate Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3466 holding.
BlackRock Fund Advisors first reported a position in Fate Therapeutics in Q1 2014 and has held it in 12 quarters since.
BlackRock Fund Advisors's Fate Therapeutics position peaked at $415K in Q2 2015.
37 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.